Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02966795




Registration number
NCT02966795
Ethics application status
Date submitted
15/11/2016
Date registered
17/11/2016
Date last updated
30/07/2021

Titles & IDs
Public title
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
Scientific title
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
Secondary ID [1] 0 0
2016-003192-22
Secondary ID [2] 0 0
M16-126
Universal Trial Number (UTN)
Trial acronym
ENDURANCE-5 6
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C Virus (HCV) 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Glecaprevir/Pibrentasvir

Experimental: Glecaprevir/Pibrentasvir for 8 Weeks - Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.

Experimental: Glecaprevir/Pibrentasvir for 12 Weeks - Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.


Treatment: Drugs: Glecaprevir/Pibrentasvir
Fixed-dose combination tablets taken orally once a day.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
Timepoint [1] 0 0
12 weeks after last dose of study drug (week 20 or 24 depending on the treatment regimen)
Secondary outcome [1] 0 0
Percentage of Participants With On-treatment HCV Virologic Failure
Timepoint [1] 0 0
8 or 12 weeks (depending on the treatment regimen)
Secondary outcome [2] 0 0
Percentage of Participants With Relapse
Timepoint [2] 0 0
End of treatment (week 8 or 12 depending on the treatment regimen) through 12 weeks after the end of treatment.

Eligibility
Key inclusion criteria
- Screening laboratory result indicating hepatitis C virus (HCV) GT5 or 6 infection.

- Participant has a positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid
(RNA) greater than or equal to 1000 IU/mL at Screening Visit.

- Participant must be HCV treatment-naïve (i.e., has never received a single dose of any
approved or investigational anti-HCV medication) or treatment-experienced (i.e., has
failed prior interferon [IFN] or pegylated interferon [pegIFN] with or without
ribavirin [RBV], or sofosbuvir [SOF] plus RBV with or without pegIFN therapy). Prior
HCV treatment with any other approved or investigational medications is not allowed.
Previous HCV treatment must have been completed greater than or equal to 2 months
prior to screening.

- Participant must be documented as having no cirrhosis or compensated cirrhosis.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Female participant who is pregnant, breastfeeding, or is considering becoming pregnant
during the study or for approximately 30 days after the last dose of study drug.

- Recent (within 6 months prior to study drug administration) history of drug or alcohol
abuse that could preclude adherence to the protocol in the opinion of the
investigator.

- Positive test result at screening for hepatitis B surface antigen (HBsAg) or
anti-human immunodeficiency virus antibody (HIV Ab).

- HCV genotype performed during screening indicating co-infection with more than one HCV
genotype.

- History of severe, life-threatening or other significant sensitivity to any excipients
of the study drug.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/01/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/08/2018
Sample size
Target
Accrual to date
Final
84
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Nepean Hospital Kingswood /ID# 157027 - Kingswood
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital /ID# 157025 - Herston
Recruitment hospital [3] 0 0
Royal Melbourne Hospital /ID# 157024 - Parkville
Recruitment postcode(s) [1] 0 0
2747 - Kingswood
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Pennsylvania
Country [3] 0 0
United States of America
State/province [3] 0 0
Washington
Country [4] 0 0
Belgium
State/province [4] 0 0
Kortrijk
Country [5] 0 0
Belgium
State/province [5] 0 0
Leuven
Country [6] 0 0
Canada
State/province [6] 0 0
Alberta
Country [7] 0 0
Canada
State/province [7] 0 0
Ontario
Country [8] 0 0
France
State/province [8] 0 0
Gironde
Country [9] 0 0
France
State/province [9] 0 0
Ile-de-France
Country [10] 0 0
France
State/province [10] 0 0
Clermont Ferrand
Country [11] 0 0
France
State/province [11] 0 0
Paris
Country [12] 0 0
New Zealand
State/province [12] 0 0
Auckland
Country [13] 0 0
Singapore
State/province [13] 0 0
Singapore
Country [14] 0 0
South Africa
State/province [14] 0 0
Gauteng
Country [15] 0 0
South Africa
State/province [15] 0 0
Western Cape
Country [16] 0 0
Vietnam
State/province [16] 0 0
Hanoi
Country [17] 0 0
Vietnam
State/province [17] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of
glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic
hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis
respectively.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02966795
Trial related presentations / publications
Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019 Jan;4(1):45-51. doi: 10.1016/S2468-1253(18)30341-8. Epub 2018 Nov 2.
Public notes

Contacts
Principal investigator
Name 0 0
AbbVie Inc.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02966795